諾華第二季銷售回復增長，核心營運收入持平，重申全年指引並公布多項研發里程碑

EX-99
2
nvs-20260630-99_1.htm
99.1 FINANCIAL REPORT Q2 2026

 99.1 Financial Report Q2 2026

   

 

  
 Novartis International AG

CH-4002 Basel

Switzerland

 

https://www.novartis.com

https://x.com/novartisnews

 

FINANCIAL RESULTS | FINANZERGEBNISSE

Novartis delivered sales growth in Q2 and further
advanced the pipeline; Full-year guidance reaffirmed

 

Ad hoc announcement pursuant to Art. 53 LR

 

Second quarter

·Net sales grew +1% (cc1, +3% USD), with core operating income1 flat (cc and USD)

oSales growth driven by priority brands including Kisqali (+43% cc), Kesimpta (+32% cc), Scemblix (+89% cc), Pluvicto
(+43% cc) and Leqvio (+59% cc)

oCore operating income margin1 was 41.2%, -70 basis points (cc)

·Q2 operating income declined -3% (cc, -2% USD); net income down -19% (cc and USD)

·Q2 core EPS1 declined -1% (cc, 0% USD) to USD 2.41

·Q2 free cash flow1 was USD 5.6 billion (-12% USD)

·H1 net sales down -2% (cc, +1% USD) with core operating income -7% (cc, -6% USD)

·Q2 selected innovation milestones:

oRhapsido EC and JP approval in CSU, Phase III CIndU data presented at EAACI

oItvisma EC approval as the only gene replacement therapy for a broad SMA patient population

oKisqali 6-year eBC follow up data showed clinically meaningful overall survival; FDA granted pediatric exclusivity,
adding a 6-month period of exclusivity to all existing patents listed in the Orange Book

oDel-zota BLA submitted to the FDA for accelerated approval in DMD

oDel-brax positive Phase I/II biomarker data in facioscapulohumeral muscular dystrophy (FSHD)

·Full-year 2026 guidance2 reaffirmed

oNet sales expected to grow low single-digit and core operating income expected to decline low
single-digit

 

Basel, July 21, 2026 – Commenting on Q2 2026 results,
Vas Narasimhan, CEO of Novartis, said:

“Novartis delivered
a solid second quarter, returning to sales growth driven by continued momentum from Kisqali, Kesimpta, Scemblix and Pluvicto.
We are encouraged by the early trajectory of our recent launches, Rhapsido in CSU and Itvisma. We also made meaningful
pipeline progress, highlighted by updated Kisqali overall survival data in early breast cancer and the FDA accelerated approval
submission for del-zota in DMD. We are on track for multiple important readouts ahead in the second half, and remain on track to deliver
our full-year guidance and mid-term outlook.”

 

 
 Key figures
  

 
  
 Q2 2026
 Q2 2025
 % change
  
 H1 2026
 H1 2025
 %
change

 
  
 USD m3
 USD m3
 USD
 cc
  
 USD m3
 USD m3
 USD
 cc

 
 Net sales
 14 408
 14 054
 3
 1
  
 27 521
 27 287
 1
 -2

 
 Operating income
 4 750
 4 864
 -2
 -3
  
 8 985
 9 527
 -6
 -7

 
 Net income
 3 257
 4 024
 -19
 -19
  
 6 413
 7 633
 -16
 -17

 
 EPS (USD)
 1.71
 2.07
 -17
 -18
  
 3.37
 3.91
 -14
 -15

 
 Free cash flow
 5 561
 6 333
 -12
  
  
 8 891
 9 724
 -9
  

 
 Core operating income
 5 940
 5 925
 0
 0
  
 10 837
 11 500
 -6
 -7

 
 Core net income
 4 578
 4 710
 -3
 -4
  
 8 372
 9 192
 -9
 -10

 
 Core EPS (USD)
 2.41
 2.42
 0
 -1
  
 4.39
 4.69
 -6
 -8

 
 

 

1. Constant currencies (cc), core results and free cash
flow are non-IFRS measures. An explanation of non-IFRS measures can be found on page 43 of the Condensed Interim Financial Report. Unless
otherwise noted, all growth rates in this Release refer to same period in prior year. 2. Please see detailed guidance assumptions on
page 7. 3. USD millions unless indicated otherwise. 

 

  

 

 

 

  

Strategy

Our focus

 

Novartis is a “pure-play” innovative medicines company.
We have a clear focus on four core therapeutic areas (cardiovascular-renal-metabolic, immunology, neuroscience and oncology), with multiple
significant in-market and pipeline assets in each of these areas, that address high disease burden and have substantial growth potential.
In addition to two established technology platforms (chemistry and biotherapeutics), three emerging platforms (gene & cell therapy,
radioligand therapy and xRNA) are being prioritized for continued investment into new R&D capabilities and manufacturing scale. Geographically,
we are focused on growing in our priority geographies – the US, China, Germany and Japan.

 

Our priorities

 

1.Accelerate growth: Renewed attention to deliver high-value medicines (NMEs) and focus on launch excellence, with a rich pipeline
across our core therapeutic areas.

2.Deliver returns: Continuing to embed operational excellence and deliver improved financials. Novartis remains disciplined and
shareholder-focused in our approach to capital allocation, with substantial cash generation and a strong capital structure supporting
continued flexibility.

3.Strengthen foundations: Unleashing the power of our people, scaling data science and technology and continuing to build trust
with society.

 

Financials

 

Second quarter

 

Net sales were USD 14.4 billion (+3%, +1% cc), with volume growth contributing
18 percentage points, offset by 14 percentage points from generic competition. Pricing had a negative impact of 3 percentage points, and
currency had a positive impact of 2 percentage points.

 

Operating income was USD 4.8 billion (-2%, -3% cc), declining mainly
due to lower gross profit, partly offset by lower SG&A expenses.

 

Net income was USD 3.3 billion (-19%, -19% cc), impacted by higher
income taxes and higher interest expense. EPS was USD 1.71 (-17%, -18% cc), benefiting from the lower weighted average number of shares
outstanding.

 

Core operating income was USD 5.9 billion (0%, 0% cc), in line with
the prior-year quarter. Core operating income margin was 41.2% of net sales, decreasing 1.0 percentage point (0.7 percentage points in
cc).

 

Core net income was USD 4.6 billion (-3%, -4% cc), mainly due to higher
interest expense. Core EPS was USD 2.41 (0%, -1% cc), benefiting from the lower weighted average number of shares outstanding.

 

Free cash flow amounted to USD 5.6 billion (-12%), due to lower net
cash flows from operating activities.

 

First half

 

Net sales were USD 27.5 billion (+1%, -2% cc), with volume growth contributing
15 percentage points, offset by 14 percentage points from generic competition. Pricing had a negative impact of 3 percentage points, and
currency had a positive impact of 3 percentage points.

 

Operating income was USD 9.0 billion (-6%, -7% cc), declining mainly
due to lower gross profit, partly offset by lower legal related costs and lower SG&A expenses.

 

 

 2

  

 

 

 

 

 

Net income was USD 6.4 billion (-16%, -17% cc), mainly due to lower
operating income, higher income taxes and higher interest expense. EPS was USD 3.37 (-14%, -15% cc), benefiting from the lower weighted
average number of shares outstanding.

 

Core operating income was USD 10.8 billion (-6%, -7% cc), declining
mainly due to lower gross profit. Core operating income margin was 39.4% of net sales, decreasing 2.7 percentage points (2.3 percentage
points in cc).

 

Core net income was USD 8.4 billion (-9%, -10% cc), mainly due to lower
core operating income and higher interest expense. Core EPS was USD 4.39 (-6%, -8% cc), benefiting from the lower weighted average number
of shares outstanding.

 

Free cash flow amounted to USD 8.9 billion (-9%), due to lower net
cash flows from operating activities.

 

Q2 priority brands

 

Underpinning our financial results in the quarter is a continued focus
on key growth drivers (ranked in order of contribution to Q2 growth) including:

 

 
 Kisqali
 (USD 1 695 million, +43% cc) sales grew strongly across all regions, with continued market share growth in the early breast cancer indication as well as leadership in metastatic breast cancer.

 
 Kesimpta
 (USD 1 424 million, +32% cc) sales grew across all regions, driven by increased demand and strong access.

 
 Scemblix
 (USD 562 million, +89% cc) sales grew across all regions, with continued strong momentum from the newly diagnosed patients-line indication in the US, Japan and Germany.

 
 Pluvicto
 (USD 651 million, +43% cc) sales showed continued strong demand in the pre-taxane metastatic castration-resistant prostate cancer (mCRPC) setting in the US, and access expansion ex-US.

 
 Cosentyx
 (USD 1 824 million, +10% cc) sales grew driven by US performance including growth in HS and IV. Ex-US, growth in Europe and most emerging markets was partly offset by a decline in China.

 
 Leqvio
 (USD 480 million, +59% cc) sales grew across all regions, with continued uptake in China following NRDL inclusion.

 
 Fabhalta
 (USD 225 million, +88% cc) sales grew, reflecting continued expansion in PNH and renal indications.

 
 Zolgensma Group
 (USD 365 million, +20% cc) sales grew driven by continued launch momentum from Itvisma in the US and UAE.

 
 Rhapsido
 (USD 64 million) continued to show strong early uptake in the US, supported by increasing coverage and a free drug program facilitating patient access. Ex-US sales were driven by early launch uptake in China.

 
 

Net sales of the top 20 brands in the second quarter and first half

 

 
  
 Q2 2026
 % change
 H1 2026
 % change

 
  
 USD m
 USD
 cc
 USD m
 USD
 cc

 
 Cosentyx
 1 824
 12
 10
 3 390
 7
 5

 
 Kisqali
 1 695
 44
 43
 3 211
 51
 48

 

 

 

 

 3

  

 

 

 

 

 
 Kesimpta
 1 424
 32
 32
 2 588
 31
 29

 
 Entresto
 1 181
 -50
 -51
 2 486
 -46
 -48

 
 Pluvicto
  651
 43
 43
 1 293
 57
 55

 
 Jakavi
  576
 10
 8
 1 133
 12
 6

 
 Tafinlar + Mekinist
  581
 1
 0
 1 074
 -5
 -7

 
 Ilaris
  550
 15
 15
 1 025
 14
 13

 
 Scemblix
  562
 89
 89
  995
 86
 85

 
 Leqvio
  480
 61
 59
  932
 68
 64

 
 Xolair
  342
 -23
 -25
  730
 -19
 -22

 
 Zolgensma Group
  365
 23
 20
  667
 7
 3

 
 Sandostatin Group
  302
 0
 -1
  589
 -5
 -7

 
 Lutathera
  225
 9
 8
  436
 9
 8

 
 Exforge Group
  191
 0
 -3
  394
 6
 2

 
 Fabhalta
  225
 88
 88
  394
 96
 94

 
 Promacta/Revolade
  179
 -64
 -65
  363
 -65
 -66

 
 Diovan Group
  160
 4
 2
  310
 2
 -2

 
 Tasigna
  142
 -57
 -58
  297
 -58
 -59

 
 Lucentis
  126
 -27
 -30
  230
 -36
 -40

 
 Top 20 brands total
 11 781
 2
 1
 22 537
 1
 -2

 
 

R&D update – key developments from the second quarter

 

New approvals

 
 
 Rhapsido

 (remibrutinib)

 EC and Japan’s MHLW approved Rhapsido as an oral treatment for adult patients with chronic spontaneous urticaria (CSU) with inadequate response to H1-antihistamine treatment. It is the first approved Bruton’s tyrosine kinase inhibitor (BTKi) for CSU.

 
 
 Itvisma

 (onasemnogene abeparvovec)

 EC approved Itvisma for the treatment of children two years and older, teens and adults living with 5q spinal muscular atrophy (SMA) with a bi-allelic mutation in the survival motor neuron 1 (SMN1) gene. It is the first and only gene replacement therapy available for this broad population.

 
 
 Fabhalta

 (iptacopan)

 In July, FDA granted traditional approval of Fabhalta as the first and only complement inhibitor to significantly slow kidney function decline in adults with primary immunoglobulin A nephropathy (IgAN) at risk of disease progression.

 
 

Regulatory updates

 
 
 Kisqali

 (ribociclib)

 FDA granted Kisqali pediatric exclusivity, adding a 6-month period of exclusivity to all existing patents listed in the Orange Book.

 
 
 KPE179

 (del-zota)

 A Biologics License Application (BLA) was submitted to the FDA for accelerated approval of del-zota in people living with Duchenne muscular dystrophy (DMD) who have a genetic variant that may be amenable to exon 44 skipping (DMD44). Del-zota previously received FDA Breakthrough Therapy designation.

 

 

 

 

 4

  

 

 

 

  

 
 
 Vanrafia

 (atrasentan)

 Regulatory submissions for traditional approval of Vanrafia in adults with IgAN were completed in the US and EU.

 
 
 Coartem

 (artemether and lumefantrine)

 The World Health Organization prequalified Coartem Baby, the first antimalarial developed specifically for newborns and young infants between 2-5 kg, a key step towards enabling widespread access through public sector procurement.

 
 

Results from ongoing trials and other highlights

 
 
 Rhapsido

 (remibrutinib)

 
 In the Phase III RemIND study, Rhapsido met its primary endpoint
 across the three most common chronic inducible urticaria (CIndU) subtypes, with higher rates of complete responses at Week 12, and responses
 seen as early as Week 2 in two subtypes. Twice as many patients achieved symptom control compared with placebo. The safety profile was
 favorable with no liver safety concerns. Data supports its potential as a first targeted therapy for CIndU. Data were presented at EAACI.

  

 The Phase IIIb REMIXED extension study in CSU demonstrated that patients
 continuing remibrutinib treatment had a 72% lower risk of relapse and maintained higher rates of disease control compared with those switched
 to placebo for up to 18 months. The safety profile remained favorable. Data were presented at EAACI. The extension study will continue
 with follow-up for 3 years.

 
 
 Pluvicto

 (lutetium Lu177 vipivotide tetraxetan)

 
 Subgroup analyses from the Phase III PSMAddition study of Pluvicto
 plus standard of care (SoC) (ARPI + ADT) in patients with PSMA+ metastatic hormone-sensitive prostate cancer (mHSPC)1 demonstrated
 consistent improvement in radiographic progression-free survival (rPFS) versus SoC alone, regardless of disease volume or presentation
 (de novo or recurrent). The benefit was comparable with the previously reported primary endpoint showing a 28% reduction in the risk of
 progression or death, with a consistent safety profile. Data were presented at ASCO.

  

 Further PSMAddition data showed Pluvicto plus SoC achieved a
 higher frequency and depth of PSA response versus SoC alone in PSMA+ mHSPC, with a 58% reduction in the risk of PSA progression. Data
 were presented at AUA.

 
 
 Cosentyx

 (secukinumab)

 In the Phase III REPLENISH study, Cosentyx demonstrated statistically significant sustained remission versus placebo at Week 52 in patients with polymyalgia rheumatica (PMR), doubling remission rates, while also reducing cumulative glucocorticoid exposure, with a safety profile consistent with Cosentyx. Data were published at the New England Journal of Medicine and presented at EULAR. Data have been submitted for health authority review in the US, EU and Japan.

 
 VAY736 (ianalumab)
 In the Phase III NEPTUNUS-1 and -2 studies in adult patients with Sjögren’s Disease, ianalumab demonstrated consistent improvement across most ESSDAI domains, including key lymphadenopathy, PNS, muscular and pulmonary domains. In the NEPTUNUS extension study, deepening control of disease activity was observed, with continued reductions in ESSDAI at Week 108 and a favorable safety profile. Data were presented at EULAR. Data have been submitted for health authority review in the US, EU and Japan.

 
 
 Vanrafia

 (atrasentan)

 Final 30-month results from the Phase III ALIGN study showed Vanrafia achieved a clinically meaningful slowing of kidney function decline in adults with IgAN together with sustained proteinuria reductions. The benefits were consistent across kidney function measures and in patient groups receiving SGLT2 inhibitors. The safety profile was consistent with prior studies. Results were published in The Lancet and presented at ERA.

 
 DWH213(del-brax)

 

 The biomarker cohort of the FORTITUDE Phase I/II study of del-brax in patients with facioscapulohumeral muscular dystrophy (FSHD) met
its primary and key secondary

 

 

 

 5

  

 

 

 

 

 
 
 

 endpoints, with reductions in KHDC1L (cDUX) and creatine kinase biomarker levels, indicating both strong target engagement and reduction in muscle damage. The safety profile was consistent with previous findings.

 
 
 Scemblix

 (asciminib)

 Week 144 data from the pivotal Phase III ASC4FIRST study of Scemblix in adults with newly diagnosed Ph+ CML-CP demonstrated superior major molecular response (MMR) compared with all SoC tyrosine kinase inhibitors (TKIs), including a 15.2% higher MMR rate versus 2G TKIs. Scemblix showed fewer grade ≥3 AEs and less than half the discontinuation rate due to AEs. Data were presented at ASCO.

 
 
 Kisqali

 (ribociclib)

 
 The NATALEE six-year follow up study showed clinically meaningful overall
 survival (OS) in the broadest at risk early breast cancer (eBC) population. Data will be presented at an upcoming medical congress.

  

 In the largest CDK4/6i biomarker analysis in HR+/HER2- eBC, NATALEE
 showed Kisqali plus non-steroidal aromatase inhibitor (NSAI) demonstrated consistent invasive disease-free survival (iDFS) benefit
 versus NSAI alone across all PAM50 intrinsic subtypes, with greater benefit trends in patients with higher genomic risk or proliferation
 signature scores, including high-risk node-negative (N0) disease. Data were presented at ASCO.

 
 
 HTT227

 (Votoplam)

 In the 24-month interim analysis of the Phase II PIVOT-HD long-term extension study, votoplam 10 mg dose demonstrated sustained mHTT lowering in early stage Huntington's disease (HD) patients with a favorable safety profile. The Phase III INVEST-HD study is actively enrolling.

 
 
 FUB523

 (zigakibart)

 
 Long-term data from the Phase I/II study of zigakibart showed durable
 reductions in disease-relevant biomarkers, including Gd-IgA1 and IgA through Week 124, alongside clinically meaningful reductions in proteinuria
 and stabilization of eGFR, with no new safety signals. Data were presented at ERA.

  

 Zigakibart is currently being evaluated in the Phase III BEYOND study
 in adults with IgAN, with readout anticipated in H1 2027.

 
 
 YTB323

 (rap-cel)

 Preliminary data from the Phase II AUTOGRAPH studies of rap-cel showed early, clinically meaningful improvements in patients with severe, refractory idiopathic inflammatory myopathies (IIM) and diffuse cutaneous systemic sclerosis (dcSSc), alongside rapid and deep B-cell depletion, with a manageable safety profile.

 
 
 225Ac-PSMA-617

  

 Phase I data from the AcTION study of the actinium-based RLT Ac225-PSMA-617 showed antitumor activity, with PSA declines and radiographic responses in patients with PSMA+ metastatic castration-resistant prostate cancer2. The safety profile was manageable. Data were presented at ASCO.

 
 Selected transactions
 
 In July, Novartis entered into an agreement to acquire Myricx Bio,
 a biotechnology company developing a new class of antibody-drug conjugates (ADCs). The acquisition strengthens the Novartis oncology pipeline
 with two lead ADC assets targeting B7-H3 and HER2 and a broader payload platform with potential impact across multiple solid tumor settings.
 The transaction is expected to close in H2 2026, subject to customary closing conditions.

  

 Novartis successfully completed the acquisition of Pikavation Therapeutics,
 Inc and SNV4818, strengthening its early-stage breast cancer pipeline.

  

 Novartis successfully completed the acquisition of Excellergy including
 Exl-111, building on deep Novartis expertise in IgE biology and allergic disease.

 
 

1 Also known as prostate-specific membrane antigen (PSMA)-positive
metastatic androgen pathway modulation-naive/sensitive (mAPMN/S) prostate cancer.

2 Also known as prostate-specific membrane antigen (PSMA)-positive
metastatic androgen pathway modulation-resistant (mAPMR) prostate cancer.

 

 

 6

  

 

 

 

 

Capital structure and net debt

 

Retaining a good balance between investment in the business, a strong
capital structure, and attractive shareholder returns remains a priority.

 

During the first half of 2026, Novartis repurchased 18.2 million shares
for USD 2.8 billion on the SIX Swiss Exchange second trading line. These repurchases included 13.8 million shares (USD 2.1 billion) under
the up-to USD 10 billion share buyback announced in July 2025 (with up to USD 5.6 billion still to be executed). In addition, 4.4 million
shares (USD 0.7 billion) were repurchased to mitigate the anticipated full-year dilution related to participation plans of associates,
with the remainder of repurchases for this purpose to be executed in H2 2026. A further 2.0 million shares (USD 0.3 billion) were repurchased
from employees. During the same period, USD 0.6 billion equity-based compensation plans expenses were recognized to equity and 12.7 million
shares were delivered to employees related to equity-based compensation plans from prior years. As a result, the total number of shares
outstanding decreased by 7.5 million compared to December 31, 2025. These treasury share transactions resulted in an equity decrease of
USD 2.4 billion and cash outflows of USD 3.1 billion.

 

Net debt increased to USD 39.4 billion at June 30, 2026, compared to
USD 21.9 billion at December 31, 2025. The increase was mainly due to the free cash flow of USD 8.9 billion being more than offset by
the net cash outflow for M&A, intangible asset transactions and other acquisitions of USD 15.3 billion, the USD 9.1 billion annual
dividend payment and cash outflows for treasury share transactions of USD 3.1 billion.

 

As of Q2 2026, the long-term credit rating for the company is Aa3 with
Moody’s Ratings and AA- with S&P Global Ratings.

 

2026 outlook 

 
 
  

 Barring unforeseen events; growth vs. prior year in cc

 
 Net sales
 Expected to grow low single-digit

 
 Core operating income
 Expected to decline low single-digit

 
 

Foreign exchange impact 

 

If mid-July exchange
rates prevail for the remainder of 2026, the foreign exchange impact for the year would be positive 1 percentage point on net sales and
positive 1 percentage point on core operating income. The estimated impact of exchange rates on our results is provided monthly on our
website.

 

 

 

 

 

 

 

 

 7

  

 

 

 

 

Key figures1

 

 
  
 Q2 2026
 Q2 2025
 % change
  
 H1 2026
 H1 2025
 % change

 
  
 USD m2
 USD m2
 USD
 cc
  
 USD m2
 USD m2
 USD
 cc

 
 Net sales
 14 408
 14 054
 3
 1
  
 27 521
 27 287
 1
 -2

 
 Operating income
 4 750
 4 864
 -2
 -3
  
 8 985
 9 527
 -6
 -7

 
 As a % of sales
 33.0
 34.6
  
  
  
 32.6
 34.9
  
  

 
 Net income
 3 257
 4 024
 -19
 -19
  
 6 413
 7 633
 -16
 -17

 
 EPS (USD)
 1.71
 2.07
 -17
 -18
  
 3.37
 3.91
 -14
 -15

 
 Net
 cash flows from operating activities
 5 882
 6 664
 -12
  
  
 9 558
 10 309
 -7
  

 
 Non-IFRS measures
  
  
  
  
  
  
  
  
  

 
 Free cash flow  
 5 561
 6 333
 -12
  
  
 8 891
 9 724
 -9
  

 
 Core operating income
 5 940
 5 925
 0
 0
  
 10 837
 11 500
 -6
 -7

 
 As a % of sales
 41.2
 42.2
  
  
  
 39.4
 42.1
  
  

 
 Core net income
 4 578
 4 710
 -3
 -4
  
 8 372
 9 192
 -9
 -10

 
 Core EPS (USD)
 2.41
 2.42
 0
 -1
  
 4.39
 4.69
 -6
 -8

 
 

1. Constant
currencies (cc), core results and free cash flow are non-IFRS measures. An explanation of non-IFRS measures can be found on page
43 of the Condensed Interim Financial Report. Unless otherwise noted, all growth rates in this Release
refer to same period in prior year. 2. USD millions unless indicated otherwise.

 

Detailed financial results accompanying this press release are
included in the Condensed Interim Financial Report at the link below:

https://ml-eu.globenewswire.com/resource/download/4e53f554-1093-41f4-95a8-a8ea8022015a

 

Disclaimer

This communication contains forward-looking statements within
the meaning of the United States Private Securities Litigation Reform Act of 1995, that can generally be identified by words such as “expected,”
“anticipated,” “planned,” “can,” “will,” “continue,” “ongoing,”
“growth,” “launch,” “expanded,” “deliver,” “accelerate,” “guidance,”
“outlook,” “priority,” “potential,” “momentum,” “on track,” “look forward,”
“pipeline,” or similar expressions, or by express or implied discussions regarding: potential new products, potential new
indications for existing products, potential product launches or potential future revenues from any such products; or results of ongoing
clinical trials; potential future, pending or announced transactions; potential future sales or earnings; strategy, plans, expectations
or intentions, including discussions regarding our continued investment into new R&D capabilities and manufacturing; our capital structure.
You should not place undue reliance on these statements. Such forward-looking statements are based on the current beliefs and expectations
of management regarding future events and are subject to significant known and unknown risks and uncertainties. Should one or more of
these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those
set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this
communication will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular
time. Nor can there be any guarantee that such products will be commercially successful in the future. Neither can there be any guarantee
that the expected benefits or synergies from the transactions described in this communication will be achieved in the expected timeframe,
or at all. In particular, our expectations could be affected by, among other things, uncertainties concerning: global healthcare cost
containment, including ongoing government, payer and general public pricing and reimbursement pressures and requirements for increased
pricing transparency; the success of key products, commercial priorities and strategy; the research and development of new products, including
clinical trial results and additional analysis of existing clinical data; our ability to obtain or maintain proprietary intellectual property
protection, including the ultimate extent of the impact on Novartis of the loss of patent protection and exclusivity on key products;
our ability to realize the strategic benefits, operational efficiencies or opportunities expected from our external business opportunities;
the development or adoption of new technologies, including artificial intelligence, and new business models; the implementation of our
new IT projects and systems; potential significant breaches of information security or disruptions of our information technology systems;
actual or potential legal proceedings, including regulatory actions or delays or government regulation related to the products and pipeline
products described in this communication; safety, quality, data integrity, or manufacturing issues; our performance on and ability to
comply with environmental, social and governance measures and requirements; major macroeconomic

 

 

 

 8

  

 

 

 

 

 

and geo- and socio-political developments, including the
impact of any potential tariffs on our products or the impact of war in certain parts of the world; future global exchange rates; future
demand for our products; and other risks and factors referred to in Novartis AG’s most recently filed Form 20-F and in subsequent
reports filed with, or furnished to, the US Securities and Exchange Commission. Novartis is providing the information in this communication
as of this date and does not undertake any obligation to update any forward-looking statements as a result of new information, future
events or otherwise.

 

All product names appearing in italics are trademarks owned
by or licensed to Novartis.

 

About Novartis 

Novartis is an innovative
medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals
and societies are empowered in the face of serious disease. Our medicines reach more than 300 million
people worldwide.

 

Reimagine medicine
with us: Visit us at https://www.novartis.com
and connect with us on LinkedIn,
Facebook, X/Twitter
and Instagram.

 

Novartis will conduct a conference call with investors to discuss
this news release today at 14:00 Central European time and 8:00 Eastern Time. A simultaneous webcast of the call for investors and other
interested parties may be accessed by visiting the Novartis website. A replay will be available after the live webcast by visiting https://www.novartis.com/investors/event-calendar.

 

Detailed financial results accompanying this press release are included
in the Condensed Interim Financial Report at the link below. Additional information is provided on our business and pipeline of selected
compounds in late-stage development. A copy of today's earnings call presentation can be found at https://www.novartis.com/investors/event-calendar.

 

Important dates 

 October 27, 2026
 Third
quarter & nine months 2026 results

 November 18-19,
2026
 Meet Novartis Management 2026 (London, UK)

 February 3, 2027
 Fourth quarter & full year 2026 results

 
 

 

 

# # #

 

 

 
 
 Novartis Media Relations

 E-mail: [email protected]

  

  
  

 
  
  
  
  

 
 
 Novartis Investor Relations

 Central investor relations line: +41 61 324 7944

 E-mail: [email protected]

  

  

 
  
  
  
  

 
 

 

 

 

 

 

 

 

 

 9